Mass Tort brief
Camp Lejeune Trials Slated and Pharma MDL Pressures Mount
Historic toxic water bench trials near in North Carolina while federal courts advance major medical device, GLP-1, and cosmetic liability dockets.
Mass Tort
The first Camp Lejeune bench trials are finally underway — putting toxic water causation before federal judges as the court pressures the government toward a global multi-billion-dollar settlement.
BackgroundThe Camp Lejeune Justice Act of 2022 allowed military veterans and families to file federal tort claims against the government for toxic drinking water exposure at the Marine Corps base. However, administrative processing backlogs have left over 408,000 filed claims unresolved in administrative review.
- The initial test trials, beginning with Mousser v. United States, examine whether exposure to industrial solvents caused kidney cancer and urothelial carcinoma.
- Federal disclosures show the Justice Department and Navy have paid over $879 million through the voluntary Elective Option settlement framework to date.
- The four presiding judges ordered weekly settlement master conferences to accelerate framework terms for hundreds of thousands of remaining claims.
Mass Tort
With 12,000 cancer claims consolidated in Chicago, the hair relaxer MDL is narrowing its bellwether trial pool — setting up a decisive causation showdown for 2027.
BackgroundThe multidistrict litigation in Chicago alleges cosmetic companies marketed hair relaxer products containing endocrine-disrupting chemicals and phthalates that penetrated the scalp to cause reproductive malignancies. Defendant manufacturers maintain that chemical straightening products comply with existing cosmetic regulations.
- The court lifted discovery stays against secondary manufacturing defendants, ordering joint proposals to finalize the five primary test cases that will shape global settlement valuations.
- Summary judgment motions and scientific causation reviews under Rule 702 are scheduled for early 2027 to determine whether plaintiffs' epidemiological testimony meets federal evidentiary standards.
- Scrutiny intensified around lead defendant L'Oréal after reports indicated the cosmetics conglomerate evaluated corporate restructuring options to ring-fence mounting product liability exposures in U.S. operations.
Mass Tort
The Abbott spinal cord stimulator MDL is accelerating into discovery — forcing the medical device maker to defend battery failure allegations in coordinated federal court.
BackgroundSpinal cord stimulators are surgically implanted neurostimulation devices that deliver electrical impulses to the spinal column to block chronic pain signals. The Judicial Panel on Multidistrict Litigation rejected an industry-wide consolidation, establishing separate litigation dockets for each major device manufacturer.
- Judge Jenkins entered initial Case Management Orders establishing standardized master pleadings, evidence preservation protocols, and discovery schedules to streamline hundreds of incoming federal complaints.
- Lawsuits allege Abbott's Proclaim and Eterna devices suffered premature battery failures and component malfunctions, forcing patients into high-risk revision surgeries to remove defective implants.
- Abbott argued its devices complied with federal premarket approval standards, asserting that reported surgical complication rates matched expected clinical parameters across the neuromodulation sector.
Mass Tort
Lawsuits claiming Dupixent masks and accelerates rare lymphomas are consolidating in federal court — challenging the safety label of one of the world's best-selling biologics.
BackgroundDupixent is an injectable biologic therapy approved to treat moderate-to-severe eczema, asthma, and chronic rhinosinusitis by inhibiting interleukin signaling. Cutaneous T-cell lymphoma is a rare, slow-growing cancer of the lymphatic system that manifests as severe, itchy skin lesions resembling persistent eczema.
- Lawsuits allege the drug masks initial cancer lesions while suppressing immune surveillance mechanisms that would normally control malignant T-cells, delaying vital cancer diagnoses for years.
- Plaintiffs applied to coordinate dozens of state-court actions into a unified Multicounty Litigation docket in New Jersey alongside federal MDL 3180 to fast-track evidence sharing.
- The FDA prescribing label does not carry a black-box warning for cutaneous lymphoma, making the drugmakers' internal pharmacovigilance timeline the central legal dispute in upcoming discovery.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
